What is CagriSema?
CagriSema is the cagrilintide plus semaglutide combination, pairing amylin/calcitonin-receptor activity with GLP-1 signaling in obesity and type 2 diabetes trials.
CagriSema dosage snapshot
- Route
- subQ
- Dose range
- 2.4 mg + 2.4 mg
- Frequency
- 1x weekly
- Duration
- 16-32+ weeks in trials
Based on reported research sources; not a dosing instruction.
Potential benefits
- Weight management
- Appetite control
- Glucose control
- Metabolic health
- Body composition
Safety profile
Unknown risk- Common: Route-specific irritation or tolerability issues may be reported depending on the compound.
- Less common: Headache, fatigue, appetite changes, or GI discomfort can appear in community or study contexts.
- Caution: Risk depends on dose, route, study model, duration, compound quality, and whether human data exists.
Storage and handling
Store according to product-label instructions and batch handling notes. Lyophilized research peptides are commonly kept dry, protected from light, and handled with clean laboratory technique.